Provided by Tiger Trade Technology Pte. Ltd.

Arcutis Biotherapeutics Inc.

23.91
-0.0600-0.25%
Volume:96.09K
Turnover:2.30M
Market Cap:2.99B
PE:111.00
High:24.11
Open:23.79
Low:23.79
Close:23.97
52wk High:31.77
52wk Low:15.13
Shares:125.07M
Float Shares:111.18M
Volume Ratio:0.34
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2154
EPS(LYR):-0.1269
ROE:15.86%
ROA:5.09%
PB:13.56
PE(LYR):-188.48

Loading ...

Arcutis Director Terrie Curran Disposes of Common Shares Worth $279,129.66

Reuters
·
Aug 29

Is Arcutis Biotherapeutics (ARQT) Stock Too Rich To Stay Reasonable?

Simply Wall St.
·
Aug 27

Insider Move at Arcutis Biotherapeutics Sends Strong Signal to Investors

TIPRANKS
·
Aug 25

Arcutis Biotherapeutics Director Terrie Curran Disposes of 1,072 Common Shares Worth $27,927.31

Reuters
·
Aug 25

Oruka Therapeutics Names Todd Edwards Chief Commercial Officer

Reuters
·
Aug 25

Top Arcutis Executive Makes Notable Move With Latest Stock Sale

TIPRANKS
·
Aug 22

Arcutis-Backed Phase 3 ZORYVE Foam Study Targets Growth in Seborrheic Dermatitis

TIPRANKS
·
Aug 22

Arcutis Biotherapeutics' Zoryve Gets Health Canada Approval for Children With Atopic Dermatitis

MT Newswires Live
·
Aug 21

Arcutis Canada: Przoryve Cream 0.05% Receives Health Canada Approval for Children Aged 2 to 5 Years with Mild to Moderate Atopic Dermatitis

THOMSON REUTERS
·
Aug 21

Arcutis Biotherapeutics Director Howard G. Welgus Sells 4,730 Common Shares for $123,835.71

Reuters
·
Aug 20

Arcutis EVP, Chief Medical Officer Patrick Burnett Disposes of USD 392,075.19 in Common Shares

Reuters
·
Aug 14

Arcutis Targets Real-World Itch Relief Data With New Phase 4 Roflumilast Study

TIPRANKS
·
Aug 14

Arcutis Biotherapeutics Earnings Call Highlights Growth Momentum

TIPRANKS
·
Aug 12

Arcutis Biotherapeutics Rilis Transkrip Paparan Kinerja Kuartal II 2026

Reuters
·
Aug 12

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Biohaven Ltd. (BHVN)

TIPRANKS
·
Aug 11

Arcutis Biotherapeutics (ARQT) Could Be 31% Undervalued Following Profit And Higher Guidance

Simply Wall St.
·
Aug 10

Arcutis Biotherapeutics Grants 143,500 RSUs, 37,000 Stock Options to New Hires Under Inducement Plan

Reuters
·
Aug 08

Arcutis Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 08

Did Profitability, Higher 2026 Guidance, and New Commercial Leadership Just Recast Arcutis Biotherapeutics' (ARQT) Investment Narrative?

Simply Wall St.
·
Aug 06

Arcutis Biotherapeutics is Maintained at Buy by Guggenheim

Dow Jones
·
Aug 06